Quick Answer
Immunome Inc. reported Total Revenue of $6.94 million for fiscal year 2025.
Immunome Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.94M -23.2% |
$9.04M -35.5% |
$14.02M | — | — | — |
| Revenue (ASC 606) | $6.94M -23.2% |
$9.04M -35.5% |
$14.02M | — | — | — |
| Net Income | -$212.39M +27.5% |
-$292.96M -174.3% |
-$106.81M -189.5% |
-$36.90M -49.3% |
-$24.71M -38.5% |
-$17.84M -70.8% |
| Diluted EPS | -$2.43 +51.4% |
-$5.00 +7.1% |
-$5.38 -74.1% |
-$3.09 -44.4% |
-$2.14 +59.3% |
-$5.26 |
| Total Assets | $683.19M +184.4% |
$240.24M +61.7% |
$148.54M +517.7% |
$24.05M -58.5% |
$57.92M +30.1% |
$44.52M +779.9% |
| Cash and Equivalents | $653.48M +355.9% |
$143.35M +45.3% |
$98.68M +385.6% |
$20.32M -58.7% |
$49.23M +23.8% |
$39.77M +1463.7% |
| Long-Term Debt | — | — | — | — | — | $134.0K |
| Stockholders Equity | $634.34M +250.1% |
$181.16M +51.1% |
$119.88M +619.9% |
$16.65M -65.4% |
$48.19M +16.5% |
$41.34M +216.0% |
| R&D Expense | $177.29M +36.9% |
$129.54M +461.1% |
$23.09M -0.8% |
$23.27M +64.9% |
$14.11M +88.5% |
$7.49M -15.2% |
| Operating Income | -$224.11M +26.7% |
-$305.80M -179.2% |
-$109.53M -196.8% |
-$36.90M -46.4% |
-$25.20M -105.6% |
-$12.26M -18.5% |
| Shares Outstanding | 113.13M +75.5% |
64.46M +49.0% |
43.25M +256.6% |
12.13M +0.2% |
12.11M +13.9% |
10.63M +867.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$57.46M | -22.0% | -32.4% |
| Diluted EPS | September 30, 2025 | -$0.65 | +16.7% | -30.0% |
| Total Assets | September 30, 2025 | $299.38M | +16.5% | +1.0% |
| Cash and Equivalents | September 30, 2025 | $272.64M | +75.3% | +89.5% |
| Long-Term Debt | March 31, 2021 | $134.0K | — | +0.0% |
| Stockholders Equity | September 30, 2025 | $263.92M | +22.8% | -2.0% |
| R&D Expense | September 30, 2025 | $49.19M | +32.2% | +21.6% |
| Operating Income | September 30, 2025 | -$60.14M | -19.0% | -29.4% |
| Shares Outstanding | September 30, 2025 | 91.71M | +51.8% | +5.4% |
- Immunome Inc. reported Total Revenue of $6.94 million for fiscal year 2025.
- Immunome Inc. showed a decrease of -23.2% in Total Revenue compared to the prior fiscal year.
- Immunome Inc. reported Revenue (ASC 606) of $6.94 million for fiscal year 2025.
- Immunome Inc. showed a decrease of -23.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Immunome Inc. reported Net Income of -$212.39 million for fiscal year 2025.
- Immunome Inc. showed an increase of +27.5% in Net Income compared to the prior fiscal year.
- Immunome Inc. reported Diluted EPS of $2.43 per share (loss) for fiscal year 2025.
- Immunome Inc. showed an increase of +51.4% in Diluted EPS compared to the prior fiscal year.
- Immunome Inc. reported Total Assets of $683.19 million for fiscal year 2025.
- Immunome Inc. showed an increase of +184.4% in Total Assets compared to the prior fiscal year.
- Immunome Inc. reported Cash and Equivalents of $653.48 million for fiscal year 2025.
- Immunome Inc. showed an increase of +355.9% in Cash and Equivalents compared to the prior fiscal year.
- Immunome Inc. reported Long-Term Debt of $134.0 thousand for fiscal year 2020.
- Immunome Inc. reported Stockholders Equity of $634.34 million for fiscal year 2025.
- Immunome Inc. showed an increase of +250.1% in Stockholders Equity compared to the prior fiscal year.
- Immunome Inc. reported R&D Expense of $177.29 million for fiscal year 2025.
- Immunome Inc. showed an increase of +36.9% in R&D Expense compared to the prior fiscal year.
- Immunome Inc. reported Operating Income of -$224.11 million for fiscal year 2025.
- Immunome Inc. showed an increase of +26.7% in Operating Income compared to the prior fiscal year.
- Immunome Inc. reported Shares Outstanding of 113.13 million shares for fiscal year 2025.
- Immunome Inc. showed an increase of +75.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: